The trial was designed to assess the safety of the vaccine and to determine whether it could expand the number of IFN-γ-producing CD8+ and CD4+ T cells specific to mutant KRAS in patients at high risk of developing PDA [134]. The gene discussed is KRAS; the disease is Patent ductus arteriosus.